At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 9 enrolled
Drug / intervention
Sorafenibdrug
Likely dose
Sorafenib 800 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2 Study of Sorafenib in Patients With Metastatic Renal Cell Carcinoma at Stanford University
In Brief
A Phase 2 clinical trial evaluating Sorafenib for Carcinoma, Renal Cell and 2 related conditions. Completed, enrolled 9 participants across 1 site.
Detailed Summary
Determine time-to-progression (TTP) for an escalating dose schedule for subjects with progressive metastatic renal cell carcinoma treated with sorafenib
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCarcinoma, Renal Cell, Kidney Disease, Kidney Cancer
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartDec 2007
First PostedMar 2009
Primary CompletionJul 2009
Study CompletionJan 2011
TodayJul 2026
First PostedMar 3, 2009
Enrollment StartDec 1, 2007
Primary CompletionJul 1, 2009
Study CompletionJan 1, 2011
TodayJul 2, 2026
Enrollment to primary: 1.6 yearsPosted 17.3 years ago
Interventions
Sorafenibdrug
Sorafenib administered in escalating 28-days cycles (400, 600 and 800 mg BID)